Key Drivers
- Strong Free Cash Flow
- Thin Profit Margins
- Tight Liquidity Position
AIAI Summary
INNV has evolved from a turnaround bet into an execution test: its strong census growth, 9.6% adjusted EBITDA margin, and free-cash-flow generation must translate into durable GAAP profitability despite slower reimbursement growth and loss-making Florida expansion; investors should demand fiscal-2027 margin resilience and EBITDA delivery near the $105–$115M guide before underwriting further upside at its premium valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Free Cash Flow
- •Thin Profit Margins
- •Tight Liquidity Position
INNV generates solid free cash flow and is improving operationally, but thin profitability, tight liquidity, negative retained earnings, and a high EV/EBITDA multiple warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Sideways trading
- •Resistance tests
- •Recent rebound
INNV is range-bound with neutral momentum; watch for a breakout above $11.03–$11.04 or support hold near $10.70–$10.75.
Sharp drop from $11.03 to $10.60 on 2026-09-10
Sentiment & News
Key News Insights:
- •EBITDA expansion
- •Census growth
- •Earnings miss
InnovAge's stronger revenue, census, EBITDA, and institutional buying signal improving fundamentals, though its earnings miss may temper near-term sentiment.
Improving operations support a constructive longer-term outlook, but the EPS shortfall could pressure shares near term
Similar Companies in Healthcare
Other companies in the same sector with AI ratings